MELD Score
The MELD score estimates short‑term mortality risk in advanced liver disease using bilirubin, creatinine, and INR 1.
mg/dLumol/L
mg/dLumol/L
Indications for Use
Used to assess 3‑month mortality risk in advanced liver disease and prioritize liver‑transplant candidates, guiding urgency of listing and allocation (UNOS/EASL) 1 [Level I evidence]. Also supports risk stratification in decompensated cirrhosis, TIPS prognostication 2 [Level II evidence], and severity assessment in complications such as variceal bleeding 3 [Level II evidence].
Insights & Cautions
Provides short‑term mortality risk in advanced liver disease but underestimates severity when extrahepatic organ failures drive prognosis (ACLF‑3 often has high mortality even with MELD‑Na <25 1).
- Not reliable for individual post‑transplant outcome or graft acceptance decisions; evidence conflicting for DBD/DCD donors 2.
- Moderate accuracy in specific conditions (AUC ~0.69 in Budd–Chiari) and should not guide individual management alone 3.
- Stronger performance in TIPS (AUC 0.81 for 90‑day mortality) but no absolute cutoff; interpret in clinical context 4.